Pharming Group Expects 2024 Total Revenue Of $280M-$295M (14% To 20% Growth), With Quarterly Fluctuations Expected
Portfolio Pulse from Benzinga Newsdesk
Pharming Group projects 2024 revenues between $280M and $295M, reflecting 14% to 20% growth. The company plans to expand its patient base for Joenja® therapy, increase ex-U.S. revenues, complete clinical trials, and seek regulatory approvals in multiple regions. Operating costs will be managed without significant cash burn, and potential acquisitions are being considered.
August 01, 2024 | 5:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pharming Group expects 2024 revenues between $280M and $295M, indicating 14% to 20% growth. The company plans to expand its patient base for Joenja® therapy, increase ex-U.S. revenues, complete clinical trials, and seek regulatory approvals in multiple regions. Operating costs will be managed without significant cash burn, and potential acquisitions are being considered.
The projected revenue growth and strategic plans for expanding Joenja® therapy, increasing ex-U.S. revenues, and seeking regulatory approvals are positive indicators for Pharming Group's future performance. The company's ability to manage operating costs without significant cash burn and its focus on potential acquisitions further support a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100